Exagen Inc.XGNNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank38
3Y CAGR-51.2%
5Y CAGR-35.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-51.2%/yr
Quarterly compound
5Y CAGR
-35.9%/yr
Recent deceleration
Percentile
P38
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.56% |
| Q3 2025 | 16.66% |
| Q2 2025 | 15.50% |
| Q1 2025 | -22.46% |
| Q4 2024 | 11.82% |
| Q3 2024 | 25.61% |
| Q2 2024 | 11.33% |
| Q1 2024 | -1.58% |
| Q4 2023 | -23.14% |
| Q3 2023 | 10.85% |
| Q2 2023 | 12.17% |
| Q1 2023 | -58.31% |
| Q4 2022 | 13.39% |
| Q3 2022 | -11.42% |
| Q2 2022 | 27.80% |
| Q1 2022 | -4.45% |
| Q4 2021 | 26.55% |
| Q3 2021 | -8.03% |
| Q2 2021 | 34.85% |
| Q1 2021 | 20.43% |
| Q4 2020 | 14.44% |
| Q3 2020 | 35.55% |
| Q2 2020 | 18.45% |
| Q1 2020 | 12.01% |
| Q4 2019 | 11.64% |
| Q3 2019 | -14.07% |
| Q2 2019 | 15.01% |
| Q1 2019 | -3.75% |
| Q4 2018 | 1.52% |
| Q3 2018 | -17.84% |
| Q2 2018 | 22.41% |
| Q1 2018 | 0.00% |
| Q4 2015 | 34.08% |
| Q3 2015 | -10.12% |
| Q2 2015 | 18.09% |
| Q1 2015 | -15.56% |
| Q4 2014 | 5.15% |
| Q3 2014 | -10.81% |
| Q2 2014 | 54.17% |
| Q1 2014 | 4.35% |